EUVIMEDEUVIMED entdecken
Crossref

Real-World Treatment Outcomes in Patients With Ga68-PSMA-PET Positive Metastatic Hormone-Sensitive Prostate Cancer With or Without Conventional Imaging Correlates

Wadih Issa, Maureen Aliru, Song Zhang, Damla Gunenc, Changchuan Jiang, Qian Qin, Suzanne Cole, Waddah Arafat, Jue Wang, Daniel Yang, Neil Desai, Aurelie Garant und 8 weitere

Clinical Genitourinary Cancer · 2026-02 · 24 (1) · 102476

DOI: 10.1016/j.clgc.2025.102476 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Genitourinary Cancer, 2026-02. Verfasst von Wadih Issa und 19 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant, Androgen Receptor Antagonists. Die Arbeit nennt 24 Literaturangaben. Gefördert von: Cancer Prevention and Research Institute of Texas.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging is highly sensitive, enabling detection of disease not visualized on conventional imaging, and leading to a new disease state: PSMA-avid/CT-negative metastatic prostate cancer. The optimal management and treatment outcomes for this group remain poorly defined. We investigated whether treatment intensification with androgen receptor signaling inhibitors (ARSI) provides additional benefit for these patients. METHODS: We conducted a retrospective study of patients with metastatic hormone-sensitive prostate cancer (mHSPC) diagnosed via standard-of-care PSMA PET/CT imaging (Ga68 gozetotide/PSMA-11) at our institution. Patients were stratified based on whether PSMA-avid lesions (SUVmax > 2.5) had correlates on conventional imaging: PSMA (+)/CT (-) versus PSMA (+)/CT (+). We compared prostate-specific antigen progression-free survival (PSA PFS) and castration resistance-free survival (CRFS) between cohorts. OS was not assessed. RESULTS: Among 159 patients, 81 (51%) had PSMA (+)/CT (-) and 78 (49%) had PSMA (+)/CT (+) disease. With a median follow up of 23 months, patients with PSMA (+)/CT (-) mHSPC had significantly longer PSA PFS (hazard ratio [HR] 0.31, P = .01) and CRFS (HR 0.08, P < .001). Within the PSMA (+)/CT (-) cohort, ARSI intensification did not improve CRFS compared to androgen deprivation therapy (ADT) monotherapy (HR 0.32, P = .33). CONCLUSIONS: Patients with PSMA (+)/CT (-) mHSPC exhibit a more favorable prognosis with reduced risk of PSA progression and castration resistance compared to those with PSMA (+)/CT (+) disease. However, among patients treated with ADT alone, CRFS was similar across groups, suggesting that the benefit of ARSI intensification in PSMA (+)/CT (-) patients requires prospective validation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Positron Emission Tomography Computed TomographyProstatic NeoplasmsProstatic Neoplasms, Castration-ResistantAndrogen Receptor AntagonistsHumansMaleAgedRetrospective StudiesMiddle AgedProstate-Specific AntigenTreatment OutcomeGallium RadioisotopesAged, 80 and overGallium IsotopesGlutamate Carboxypeptidase IIAntigens, SurfaceProgression-Free SurvivalAndrogen AntagonistsNeoplasm Metastasis

Stichwörter der Autor:innen

AR treatment intensificationAndrogen deprivation therapyAndrogen receptor inhibitor intensification

Substanzen

Prostate-Specific AntigenGallium Radioisotopesgallium 68 PSMA-11Gallium IsotopesGlutamate Carboxypeptidase IIAntigens, SurfaceFOLH1 protein, humanAndrogen Receptor AntagonistsAndrogen Antagonists

Autor:innen und Institutionen

  • Division of Hematology and Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX.
  • Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX.
  • Peter O'Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dallas, TX.
  • Division of Nuclear Medicine, Department of Radiology, University of Texas Southwestern Medical Center, Dallas, TX.
  • Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX.
  • Division of Hematology and Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX; Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Da…

Förderung

  • Cancer Prevention and Research Institute of Texas

Zitieren

APA

Issa, W., Aliru, M., Zhang, S., Gunenc, D., Jiang, C., Qin, Q., Cole, S., Arafat, W., Wang, J., Yang, D., Desai, N., Garant, A., Hannan, R., Oz, O. K., Woldu, S., Lotan, Y., Roehrborn, C., Courtney, K., Wang, A. Z., & Zhang, T. (2026). Real-World Treatment Outcomes in Patients With Ga68-PSMA-PET Positive Metastatic Hormone-Sensitive Prostate Cancer With or Without Conventional Imaging Correlates. Clinical Genitourinary Cancer, 24(1), 102476. https://doi.org/10.1016/j.clgc.2025.102476

Vancouver

Issa W, Aliru M, Zhang S, Gunenc D, Jiang C, Qin Q, et al. Real-World Treatment Outcomes in Patients With Ga68-PSMA-PET Positive Metastatic Hormone-Sensitive Prostate Cancer With or Without Conventional Imaging Correlates. Clinical Genitourinary Cancer. 2026;24(1):102476. doi:10.1016/j.clgc.2025.102476

BibTeX
@article{Issa2026,
  author = {Issa, Wadih and Aliru, Maureen and Zhang, Song and Gunenc, Damla and Jiang, Changchuan and Qin, Qian and Cole, Suzanne and Arafat, Waddah and Wang, Jue and Yang, Daniel and Desai, Neil and Garant, Aurelie and Hannan, Raquibul and Oz, Orhan K and Woldu, Solomon and Lotan, Yair and Roehrborn, Claus and Courtney, Kevin and Wang, Andrew Z and Zhang, Tian},
  title = {Real-World Treatment Outcomes in Patients With Ga68-PSMA-PET Positive Metastatic Hormone-Sensitive Prostate Cancer With or Without Conventional Imaging Correlates},
  journal = {Clinical Genitourinary Cancer},
  year = {2026},
  volume = {24},
  number = {1},
  pages = {102476},
  doi = {10.1016/j.clgc.2025.102476}
}
Kostenlos starten →